Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant in Severe Insulin Resistance
NCT05470504Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jan 2023
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pegvisomant in partial lipodystrophy, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Jan 2023; status: recruiting.
02
Drugs
pegvisomant
03
Conditions
partial lipodystrophy
Beyond the preview
Go deeper on NCT05470504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470504.